TWO · 6615.TWO
Sofiva Genomics Co.,Ltd.
NT$33.10+NT$0.25 (+0.76%)
Sofiva Genomics Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 17.25% below the high.
Loading market information…
TWO · 6661.TWO · TWD
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 06:31 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
Welgene Biotech Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 18.43% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Welgene Biotech Co.,Ltd.’s forward annual dividend is NT$0.18 per share, paid annual. The forward yield is 1.09% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Welgene Biotech Co.,Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Welgene Biotech Co.,Ltd. primarily focuses on delivering genetic analysis services. The company provides comprehensive support for scientific research, employing a range of advanced laboratory techniques such as genetic sequencing, microarray analysis, qPCR verification, nucleic acid extraction and quality control, LCM single cell experimentation, and intricate bioinformatics analysis. A key offering in their portfolio is Cytoscan, an array-based comparative genomic hybridization (CGH) solution. Beyond services, Welgene Biotech also supplies essential laboratory products, including various reagents, consumable items, and specialized instruments, alongside dedicated software solutions. Established in 2003, the company operates from its headquarters in Taipei City, Taiwan.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 11:52 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$33.10+NT$0.25 (+0.76%)
Sofiva Genomics Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 17.25% below the high.
NT$9.72+NT$0.15 (+1.57%)
Health & Life Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 32.97% below the high.
NT$12.60+NT$0.15 (+1.2%)
UniPharma Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 21.25% below the high.
NT$11.70+NT$2.40 (+25.81%)
DuoGenic StemCells corporation’s quoted price sits in the lower half of its reported 52-week range, 45.58% below the high.
NT$6.97-NT$0.23 (-3.19%)
Sunder Biomedical Tech. Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 42.4% below the high.
NT$29.90-NT$0.60 (-1.97%)
A-SPINE Asia Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 26.17% below the high.
NT$7.78+NT$0.33 (+4.43%)
Pharmigene, Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.35% below the high.
NT$14.40+NT$0.35 (+2.49%)
EPS Bio Technology Corp.’s quoted price sits in the lower half of its reported 52-week range, 22.16% below the high.
